Allogeneic BMT represents the only chance of cure for b-thalassemia. Occasionally, two affected individuals from the same family share a matched healthy sibling. Moreover, a high incidence of transplant rejection is still observed in Pesaro class III patients, requiring a second BMT procedure. In these settings, one option is to perform a second BM harvest from the same donor. Although BM harvest is a safe procedure in children, ethical issues concerning this invasive practice still arise. Here, we describe our series of seven pediatric, healthy donors, who donated BM more than once in favor of their b-thalassemic HLA-identical siblings between June 2005 and January 2008. Three donors donated BM twice to two affected siblings and four donors donated twice for the same sibling following graft rejection of the first BMT. All donors tolerated the procedures well and no relevant side effects occurred. There was no significant difference between the two harvests concerning cell yield and time to engraftment. Our experience shows that for pediatric donors, a second BM donation is safe and feasible and good cellularity can be obtained. We suggest that a second harvest of a pediatric donor can be performed when a strong indication for BMT exists.
adulthood with an open-ended survival. Nevertheless, iron overload, although dramatically reduced by chelation, is not abolished. Endocrine, cardiac and hepatic complications still occur affecting quality of life and representing the principal cause of death. Moreover, in developing countries, the delivery of a regular treatment is often problematic and this worsens the prognosis for most patients. 1, 2 At present, allogeneic hematopoietic SCT represents the only chance of cure for b-thalassemia major. [3] [4] [5] This procedure may represent the only option of long-term survival for most thalassemic children living in developing countries of the Mediterranean area and the Middle East. In these areas, often more than one family member is affected and occasionally two affected individuals share one matched healthy sibling. In this context, one donor could potentially cure two affected siblings. In addition, for patients from these countries receiving BMT, a high incidence of transplant rejection is still observed, probably due to alloimmunization from non-leucodepleted blood products and extramedullary erythropoiesis due to low pretransfusion Hb threshold. 6, 7 This is particularly relevant for high-risk patients, such as Pesaro class III patients, who may benefit from a second BMT procedure from the same donor. Although BM harvest is a safe procedure in children, [8] [9] [10] such an invasive method must be balanced with ethical issues, especially when a pediatric donor is subjected to a second marrow harvest. In addition to ethical and safety concerns, there are no reports on cell yield and engraftment of the second harvest from the same donor.
We describe our series of seven pediatric, healthy donors who donated BM more than once for their b-thalassemic HLA-identical siblings.
Patients and methods
Between June 2005 and January 2008, seven pediatric donors underwent multiple BM harvests in favor of their siblings affected by b-thalassemia major at our institute. Affected siblings were referred to our hospital from Mediterranean and Middle East countries sponsored by the Mediterranean Institute of Hematology (IME).
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Indication to proceed to BMT was supported by poor medical care in the country of origin as evidenced by low pre-transfusion Hb threshold (7-8.5 g per 100 ml), irregular iron chelation and high ferritin level. Characteristics of the patients are detailed in Table 1 .
Three donors donated twice because they were HLAidentical to two affected siblings, whereas four donors donated twice for the same sibling following primary graft failure (one case) or graft rejection (three cases) after the first BMT. One donor underwent three harvest procedures: one at the first transplant and two before the second, to increase cell yield. All donors were healthy. Donors were evaluated for their eligibility by hematological, biochemical and virological analyses by serology and molecular tests according to the Italian law, as well as by chest X-ray, electrocardiogram and echocardiogram. Four donors were b-thalassemia carriers. Four donors were iron deficient and were given iron supplements before harvest. Three of them were also folic acid deficient and were supplemented. The critical decision to proceed to a second donation was taken by the transplant team on a plenary BMT meeting.
BMT counseling consists of multiple steps. Initially, a senior physician meets the entire family to discuss BMT and marrow donation point by point. The doctor meets the parents separately to discuss survival, probability of the patient being cured and the risks related to the donor. A few days later, a clinical psychologist meets the entire family and the patient and the donor separately. In particular, with regard to the donor, the psychologist assesses the understanding of the sibling's illness, compliance with medications, ability to cope with pain, fears and hopes. During treatments, the clinical psychologist meets patients and donors on the ward round and in clinic depending on the family needs. In case of transplant rejection, the entire family is involved in several sessions with the physician in charge and the clinical psychologist to discuss failure of the transplant and treatment options. In particular, the attention is focused on the donor's sense of guilt and responsibility and the patient's fears and anxieties.
Written informed consent is obtained from the donor's parents or legal guardian according to the Italian law. Depending on age and understanding, minor donors are asked the permission to donate, although this does not have legal value. As part of the consent process, the family receives written detailed explanation of the transplant process with risks and benefits.
All BM harvests were performed under general anesthesia. BM was harvested via multiple 3-5 ml aspirations bilaterally from the anterior and posterior iliac crests (target 42 Â 10 8 total nucleated cells (TNC)/kg or 42 Â 10 6 CD34 þ /kg). When a second harvest procedure was planned, the first harvest was taken only from the anterior iliac crests and the second from the posterior iliac crests to reduce the extent of tissue damage due to inflammation and, therefore, post-operative discomfort, and possibly to preserve cell yield. At the end of the harvest, local 0.75% naropine (4 mg/kg) was injected in the aspiration sites. Intravenous tramadol and paracetamol and prophylactic ceftriaxone were given post-operatively according to local protocols. Depending on the volume harvested, the hemodynamic stability of the donor and the pre-operative Hb, irradiated allogeneic blood transfusions were given, during or after the procedure. All donors were scheduled to be discharged 2 days after the procedure with oral iron and folic acid supplements. In case of ABO incompatibility and high isohemagglutinin titer, the harvest was appropriately manipulated with erythrodepletion (major incompatibility) or plasmadepletion (minor incompatibility).
Results
Seven pediatric donors underwent multiple BM harvests. The median time between the procedures was 178 days (range: 42-497). Six donors were submitted to two harvests. One donor was submitted to three BM harvests: the first harvest was used for the first BMT but, following rejection of the transplant, the affected sibling was given a second transplant 393 days after the first BMT. For this purpose, the donor was harvested twice with a 93-day interval due to an unfavorable donor/recipient weight ratio. Between the two harvests, the first was cryopreserved and infused together with the second to increase cell yield.
Concerning safety, all donors tolerated the procedures well. No relevant side effects occurred except for selflimiting pain or stiffness at the harvest site. Four donors received allogeneic blood transfusions after the first þ were therefore very similar in the two harvests with no decrease in cellularity in the second harvest (Table 2) .
Concerning efficacy of the infused marrow, recipients received a median of 4.7 Â 10 8 TNC/kg (range: 1.1-7.5) and 5.72 Â 10 6 CD34 þ /kg (range: 4.6-17.5) from the first harvest, and 4.5 Â 10 8 TNC/kg (range: 0.9-8.6) and 7.7 Â 10 6 CD34 þ /kg (range: 3.4-15.2) from the second harvest. Two harvests were submitted to erythrodepletion due to major incompatibility and two to plasmadepletion due to minor incompatibility. Engraftment occurred in all patients. However, for patient 531, technical problems with erythrodepletion of the first harvest resulted in cell damage and loss in vitality. On day 41, the patient was still thrombocytopenic, requiring daily platelets support due to platelets refractoriness and grade 3 mucocutaneous hemorrhage. This situation prompted a collegial decision to reharvest the donor 42 days after the first procedure. However, on day 1 from the second infusion, platelet engraftment was achieved. Median time to neutrophil40.5 Â 10 9 /l was 20 days (range: 13-24) and to platelet420 Â 10 9 /l was 18 days (range: 13-23) for the first harvest and 16 days (range: 14-20) and 23 days (range: 15-50), respectively, for the second harvest. Time to neutrophil and platelet engraftment was therefore very similar in the two BMTs with no delay after the second infusion.
Discussion
BMT offers the only hope of cure for children affected by b-thalassemia major. Patients from developing countries do not have access to adequate care, having irregular iron chelation and inadequate transfusion policies, leading to poor survival with medical therapy.
1,2 Conversely, thalassemia-free survival for patients receiving BMT from an HLA-identical sibling is 90% in class I, 87% in class II and 58-85% in class III. 13, 14 Moreover, thalassemia major patients should be transplanted soon, as delay in transplantation will result in escalation of risk group and dismal outcome. 3 For these reasons, clinicians who operate in the field of inherited diseases curable by BMT, such as b-thalassemia major, may face the dilemma of harvesting a healthy donor twice if he is HLA-identical to two affected siblings. Also, in case of graft rejection, which is common in the setting of poorly transfused and chelated thalassemia patients or heavily transfused aplastic anemia patients, a donor may be asked to donate twice.
Concerning the donor perspective, this individual does not receive direct medical benefit from the procedure. Therefore, the decision to perform a second BM harvest must be balanced with safety, efficacy and ethical issues. To our knowledge, there are no reports addressing this issue.
Besides pain and anxiety, already described for adult sibling donors, in the pediatric setting, the issues are even more complex because of the variable of developmental age, with a significant impact on the perception of events, which in turn impacts stress. [15] [16] [17] [18] [19] In each circumstance, we carefully explored alternative options to protect the pediatric donor from this compelled altruism. When referred to BMT, the entire family discussed BMT and marrow donation with a senior physician, who provided an age-appropriate explanation, respecting the donor's autonomy and well-being. The positive attitude to donate BM for a second time was probably influenced by the knowledge of survival probabilities and active donor participation.
Once established for each clinical context that there are medical and ethical justifications to ask a donor to donate for two affected siblings, the options to consider are (i) transplanting both patients at the same time from a single harvest; (ii) harvesting the donor once and cryopreserving half of the marrow for the second patient; (iii) harvesting the donor twice and infusing fresh BM to both recipients. We did not consider G-CSF-mobilized peripheral blood hematopoietic stem cells as an option, as this procedure is not allowed in Italy for pediatric donors. Furthermore, there are safety concerns regarding the use of G-CSF in the pediatric setting. 20 The first option was excluded to minimize the risk of myeloablating two patients with the uncertainty of obtaining the target number of stem cells for both recipients. Proper cell dose is crucial in this clinical context to maximize the chances of achieving a full donor chimerism. The second option was excluded to avoid transplantation of one patient with cryopreserved marrow, which is not the best option for allogeneic transplants; moreover, if we had opted to harvest the donor only once, we may have been limited in the volume harvested. The third solution was chosen, although this option would imply the risk and discomfort of two harvest procedures under general anesthesia.
In the context of patients experiencing graft rejection from the first transplant, the options to consider are (i) long-term medical management and (ii) performing a second transplant from alternative donors. In the patient population described here, long-term survival with medical management is uncertain. Concerning alternative donors, although transplants from well-selected unrelated donors seem to offer results comparable to those performed with siblings, 21 the possibility to find a suitable unrelated donor or cord blood for thalassemic patients of Middle Eastern origin is very low, 3, 4 and transplants from an haploidentical
Multiple BM harvests in pediatric donors E Biral et al Table 2 Harvests' characterization 3, 4 For these reasons, the decision to proceed to a second transplantation from the same family donor was taken. Several studies with large series of patients show that marrow harvest is a very safe procedure. The most frequent side effects of marrow harvest are mild and self-limiting tiredness and pain; it rarely results in morbidities or life-threatening complications. 8, 9 These severe adverse events occur mainly in aged donors and are extremely rare in children. [22] [23] [24] The donors described in this series tolerated both procedures well and did not regard the second procedure as more painful or worrisome. Four donors, with low Hb levels due to the status of b-thalassemia carrier, underwent allogeneic blood transfusion. We opted not to proceed to autologous blood collection because of low baseline Hb (donation of autologous blood would result in symptomatic anemia), young donor age and difficulties with adequate venous access.
Martinez et al. 25 described the administration of recombinant EPO and iron to 11 donors before harvesting to avoid blood transfusion; this approach was successful but the use outside clinical protocols is not a standard procedure and exposes the donors to cytokines, which may have long-term effects. Moreover, in our clinical setting, the donors receiving allogeneic transfusions were all b-thalassemia carriers with erythroid hyperplasia and ineffective erythropoiesis, and therefore might benefit only marginally from rh-EPO administration.
Finally, Kletzel et al. 26 performed red-cell salvage from the BM during the harvesting procedure. This interesting approach, however, resulted in more than 50% reduction in the TNC dose infused. We therefore decided to balance the small risk of giving an allogeneic blood transfusion with the benefit of higher levels of Hb pre-harvest, reduced discomfort for the donor and simplicity of the procedure.
Little is known regarding the efficacy of second BM harvests and it is perceived by clinicians that the second harvest could result in reduced cell yield. In our series, second harvests did not result in reduced cell yield or increased time to engraftment. Concerning efficacy of the transplantation procedure, for siblings sharing the same donor, all procedures resulted in successful engraftment and the recipients were transfusion-independent at the last follow-up. Regarding the patients who experienced graft rejection, three underwent a successful second transplantation from the same donor and were discharged to their home countries free from thalassemia. A fourth patient is currently only 3 months after second transplantation with full donor engraftment.
In conclusion, this report describes seven pediatric marrow donors undergoing multiple donations and demonstrates feasibility, safety and efficacy in terms of good cell yield and engraftment. We suggest that this strategy can be considered when a strong clinical indication to proceed to BMT exists.
